• Ana Ponte, Rolando Pinho, Margarida Mota, Joana Silva, Nuno Vieira, Rosa Oliveira, Jaime Rodrigues, Mafalda Sousa, Isabel Sousa, and João Carvalho.
• Gastrenterologia, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal.
• Rev Esp Enferm Dig. 2018 May 1; 110 (5): 311-315.

Aimthis study aimed to describe the efficacy and safety of fecal microbiota transplantation (FMT) for the treatment of refractory and recurrent Clostridium difficile infection (CDI).Methodsthis was an observational study of patients with refractory or recurrent CDI treated with FMT between June 2014 and January 2017. Primary and secondary outcomes were the resolution of diarrhea without CDI recurrence within two months after one or more FMT. A descriptive analysis was performed.Resultsthirty-four FMT were performed in 28 patients, 88.2% (n = 30) using an upper route with a gastroscopy and 11.8% (n = 4) with colonoscopy; 50% (n = 17) of FMT were due to recurrent CDI and 50% (n = 17) were due to refractory CDI. The overall cure rate of upper FMT was 87.5% (21/24) and 100% (4/4) when colonoscopy was performed. A cure was achieved after one FMT in 88% (22/25) of cases and after two or more FMT in 8% (2/25) of cases, resulting in an overall cure rate of 96% (24/25). No severe adverse events were reported.ConclusionFMT constitutes an effective and safe approach for the management of refractory and recurrent CDI, with an overall cure rate of 96% and no reported severe adverse events.

15 keywords...

hide…